Entecavir + Lamivudine + Pegylated Interferon Alfa-2A

Phase 3Completed

1 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Pediatric Immuno-Tolerant Chronic Hepatitis B

Conditions

Pediatric Immuno-Tolerant Chronic Hepatitis B

Trial Timeline

Jun 16, 2014 → Jan 29, 2020

NCT ID

NCT02263079

About Entecavir + Lamivudine + Pegylated Interferon Alfa-2A

Entecavir + Lamivudine + Pegylated Interferon Alfa-2A is a phase 3 stage product being developed by Roche for Pediatric Immuno-Tolerant Chronic Hepatitis B. The current trial status is completed. This product is registered under clinical trial identifier NCT02263079. Target conditions include Pediatric Immuno-Tolerant Chronic Hepatitis B.

What happened to similar drugs?

3 of 18 similar drugs in Pediatric Immuno-Tolerant Chronic Hepatitis B were approved

Approved (3) Terminated (0) Active (15)

✅Boosted AtazanavirBristol Myers SquibbApproved

✅Atazanavir + RitonavirBristol Myers SquibbApproved

✅IgPro10CSLApproved

🔄candsartan cilexetilAstraZenecaPhase 3

🔄basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent) + MMF, cyclosporine, steroidsNovartisPhase 3

🔄VAL489 + VAL489 matching placeboNovartisPhase 3

🔄EtanerceptAmgenPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02263079	Phase 3	Completed	Jun 16, 2014	Jan 29, 2020	Pediatric Immuno-Tolerant Chronic Hepatitis B

Competing Products

20 competing products in Pediatric Immuno-Tolerant Chronic Hepatitis B

See all competitors

Product	Company	Stage	Hype Score
Ramucirumab	Eli Lilly	Phase 1	29
erlotinib + etoposide	Astellas Pharma	Phase 2	27
Mitoxantrone Hydrochloride Liposome + Irinotecan + Vincristine	Sun Pharmaceutical	Phase 1	33
Perampanel Oral Suspension + Perampanel Tablet	Eisai	Phase 2	42
Eribulin Mesylate	Eisai	Phase 1	29
Decitabine + Decitabine	Eisai	Phase 2	27
Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily	Sumitomo Pharma	Phase 1	29
Remimazolam Tosilate for injection + Propofol Injection	Jiangsu Hengrui Medicine	Phase 2/3	45
Ceftaroline fosamil + Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam + Cephalexin or Clindamycin or Linezolid	AstraZeneca	Phase 2/3	38
candsartan cilexetil	AstraZeneca	Phase 3	40
Durvalumab / Tremelimumab Combination Therapy	AstraZeneca	Phase 1/2	36
Rotavirus Vaccine	Merck	Pre-clinical	18
basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent) + MMF, cyclosporine, steroids	Novartis	Phase 3	40
VAL489 + VAL489 matching placebo	Novartis	Phase 3	40
LCZ696 + Enalapril + Placebo of LCZ696 + Placebo of Enalapril + LCZ696	Novartis	Phase 2/3	38
Everolimus	Novartis	Phase 2	35
Corticosteroids + Cyclosporine + mycophenolate mofetil	Roche	Phase 2	27
Blinatumomab for Injection	Amgen	Phase 1	25
Etanercept	Amgen	Phase 3	40
Denosumab	Amgen	Phase 3	40